105 related articles for article (PubMed ID: 25130952)
1. Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma.
Pinto A; Signoretti S; Hirsch MS; Barletta JA
Histopathology; 2015 May; 66(6):901-4. PubMed ID: 25130952
[No Abstract] [Full Text] [Related]
2. [Molecular features of metanephric adenoma and their values in differential diagnosis].
Wang X; Shi SS; Yang WR; Ye SB; Li R; Ma HH; Zhang RS; Lu ZF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):38-42. PubMed ID: 28072975
[No Abstract] [Full Text] [Related]
3. BRAF mutations in pediatric metanephric tumors.
Chami R; Yin M; Marrano P; Teerapakpinyo C; Shuangshoti S; Thorner PS
Hum Pathol; 2015 Aug; 46(8):1153-61. PubMed ID: 26014474
[TBL] [Abstract][Full Text] [Related]
4. Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma.
Udager AM; Pan J; Magers MJ; Palapattu GS; Morgan TM; Montgomery JS; Weizer AZ; Hafez KS; Miller DC; Wolf JS; McHugh JB; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Am J Surg Pathol; 2015 Apr; 39(4):549-57. PubMed ID: 25602792
[TBL] [Abstract][Full Text] [Related]
5. Metanephric adenoma with BRAF V600K mutation and a doubtful radiological imaging: pitfalls in the diagnostic process.
Lenci N; Francesco P; Scarciglia E; Fiorentino V; Schino M; Palermo G; Racioppi M; Bassi P; Martini M
Med Mol Morphol; 2021 Jun; 54(2):187-191. PubMed ID: 33175195
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutations in metanephric adenoma of the kidney.
Choueiri TK; Cheville J; Palescandolo E; Fay AP; Kantoff PW; Atkins MB; McKenney JK; Brown V; Lampron ME; Zhou M; Hirsch MS; Signoretti S
Eur Urol; 2012 Nov; 62(5):917-22. PubMed ID: 22727996
[TBL] [Abstract][Full Text] [Related]
7. Application of BRAF V600E mutation analysis for the diagnosis of metanephric adenofibroma.
Mangray S; Breese V; Jackson CL; Lombardo K; Taliano R; Resnick M; Yakirevich E
Am J Surg Pathol; 2015 Sep; 39(9):1301-4. PubMed ID: 26274032
[No Abstract] [Full Text] [Related]
8. KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas.
Catic A; Kurtovic-Kozaric A; Sophian A; Mazur L; Skenderi F; Hes O; Rohan S; Rakheja D; Kogan J; Pins MR
BMC Med Genet; 2020 Oct; 21(1):202. PubMed ID: 33046021
[TBL] [Abstract][Full Text] [Related]
9. Metanephric Adenoma-Epithelial Wilms Tumor Overlap Lesions: An Analysis of BRAF Status.
Wobker SE; Matoso A; Pratilas CA; Mangray S; Zheng G; Lin MT; Debeljak M; Epstein JI; Argani P
Am J Surg Pathol; 2019 Sep; 43(9):1157-1169. PubMed ID: 31192863
[TBL] [Abstract][Full Text] [Related]
10. A renal metanephric adenoma showing both a 2p16e24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?
Dadone B; Ambrosetti D; Carpentier X; Duranton-Tanneur V; Burel-Vandenbos F; Amiel J; Pedeutour F
Cancer Genet; 2013; 206(9-10):347-52. PubMed ID: 24432405
[TBL] [Abstract][Full Text] [Related]
11. Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma.
Kinney SN; Eble JN; Hes O; Williamson SR; Grignon DJ; Wang M; Zhang S; Baldrige LA; Martignoni G; Brunelli M; Wang L; Comperat E; Fan R; Montironi R; MacLennan GT; Cheng L
Mod Pathol; 2015 Sep; 28(9):1236-48. PubMed ID: 26248896
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
Kuan SF; Navina S; Cressman KL; Pai RK
Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
[TBL] [Abstract][Full Text] [Related]
13. Lack of KRAS and BRAF mutation in renal cell carcinoma.
Gattenlöhner S; Etschmann B; Riedmiller H; Müller-Hermelink HK
Eur Urol; 2009 Jun; 55(6):1490-1. PubMed ID: 19282104
[No Abstract] [Full Text] [Related]
14. [BRAF mutation in colorectal serrated lesions].
Zhou ZY; Han Y; Wang LP
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3411-4. PubMed ID: 19159571
[TBL] [Abstract][Full Text] [Related]
15. VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation.
Sperveslage J; Gierke M; Capper D; Honegger J; Sipos B; Beschorner R; Schittenhelm J
Acta Neuropathol; 2013 Jun; 125(6):911-2. PubMed ID: 23589031
[No Abstract] [Full Text] [Related]
16. Cytologic and cytogenetic analysis of metanephric adenoma of the kidney: a report of two cases.
Granter SR; Fletcher JA; Renshaw AA
Am J Clin Pathol; 1997 Nov; 108(5):544-9. PubMed ID: 9353093
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution.
Chan E; Stohr BA; Croom NA; Cho SJ; Garg K; Troxell ML; Higgins JP; Bean GR
Histopathology; 2020 Jun; 76(7):1084-1090. PubMed ID: 32064677
[TBL] [Abstract][Full Text] [Related]
19. Frequent BRAF V600E Mutations in Metanephric Stromal Tumor.
Argani P; Lee J; Netto GJ; Zheng G; Tseh-Lin M; Park BH
Am J Surg Pathol; 2016 May; 40(5):719-22. PubMed ID: 26796506
[No Abstract] [Full Text] [Related]
20. Metanephric adenoma: molecular study and review of the literature.
Rodríguez-Zarco E; Machuca-Aguado J; Macías-García L; Vallejo-Benítez A; Ríos-Martín JJ
Oncotarget; 2022; 13():387-392. PubMed ID: 35198098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
